A Phase 1/2 Study to Evaluate MEDI4736

Inclusion Criteria:

Age 18 or older.
In the dose-escalation phase: histologically- or cytologically- confirmed advanced solid tumor that is refractory to standard therapy and for which no standard therapy exists.
In the dose-expansion phase: histologically- or cytologically- confirmed advanced solid tumor where if an approved first-line therapy is available, participants must have failed, be intolerant to, be ineligible for, or have refused
Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.
Adequate organ and marrow function.
Participants must have at least 1 measurable lesion.
Available archived tumor tissue sample.
Willingness to provide consent for biopsy sample (dose-expansion only)

Exclusion Criteria:

Any prior Grade ≥ 3 immune-mediated adverse event (imAE) while receiving immunotherapy
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.
Prior treatment with immunotherapy agents including, but not limited to, tumor necrosis factor receptor superfamily agonists or checkpoint inhibitors or natural killer (NK) cell inhibitors.
Active or prior documented autoimmune disease within the past 2 years
History of primary immunodeficiency
History of organ transplant that requires use of immunosuppressives
Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment
Other invasive malignancy within 2 years
Women who are pregnant or lactating
Uncontrolled intercurrent illness
Known history of tuberculosis
Known to be human immunodeficiency virus (HIV) positive
Known to be Hepatitis B or C positive (except HCC participants)